CDK4 and breast cancer: In our study, the transcriptomic analysis of mouse tumors highlighted chronic IFNγ response as a resistance driver, as previously suggested by another study that implicated the activation of the IFN pathway with intrinsic and acquired resistance to CDK4/6i in preclinical models and clinical HR+/HER2− BC samples [208].